Ukraine
Femara CAS NO.112809-51-5
- Min.Order: 0 Metric Ton
- Payment Terms:
- Product Details
Keywords
- Femara
- Benicar
- Atenolol
Quick Details
- ProName: Femara
- CasNo: 112809-51-5
- Application: Femara (generic name: letrozole; brand...
- DeliveryTime: 48 hours
- ProductionCapacity: Metric Ton/Day
- Purity: 99.9%
- LimitNum: 0 Metric Ton
Superiority
Femara (generic name: letrozole; brand names include: Letrofil / Trozet / Femar) belongs to a group of medicines called aromatase inhibitors. They are also called "antiestrogens" because they act by reducing the production of estrogen in your body.
Femara is used to treat breast cancer in women who are post-menopausal - that is, women who no longer have periods, either naturally due to their age or after surgery or chemotherapy.
Femara is approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment.
Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trial are based on 24 months of treatment.
In addition, Femara is approved for the treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer)
Details
Femara (generic name: letrozole; brand names include: Letrofil / Trozet / Femar) belongs to a group of medicines called aromatase inhibitors. They are also called "antiestrogens" because they act by reducing the production of estrogen in your body.
Femara is used to treat breast cancer in women who are post-menopausal - that is, women who no longer have periods, either naturally due to their age or after surgery or chemotherapy.
Femara is approved for the adjuvant (following surgery) treatment of postmenopausal women with hormone receptor-positive early stage breast cancer. The benefits of Femara in clinical trials are based on 24 months of treatment.
Femara is also approved for the extended adjuvant treatment of early stage breast cancer in postmenopausal women who are within three months of completion of five years of tamoxifen therapy. The benefits of Femara in clinical trial are based on 24 months of treatment.
In addition, Femara is approved for the treatment of postmenopausal women with hormone receptor-positive or hormone receptor-unknown breast cancer that has spread to another part of the body (metastatic cancer)